#Obesity medicine
Chronic weight management as a clinical specialty.
Hypothalamic Obesity in Craniopharyngioma
A 2026 review found different obesity patterns after pediatric and adult craniopharyngioma, while direct age comparisons remain absent.
Oral semaglutide cognition cohort
A retrospective cohort linked oral semaglutide with fewer new cognitive-impairment cases than DPP-4 inhibitors, but it cannot prove prevention.
Semaglutide and a thyroid cancer case
A papillary thyroid cancer case during semaglutide use cannot establish causation, and larger human studies have not confirmed excess risk.
Semaglutide, Low Testosterone, Nine Men
An exploratory study of nine men ties semaglutide to shifted DNA methylation in obesity-related low testosterone, and it is far too small to prove anything.
An RNA Therapy for Muscle Loss on GLP-1s
In mice, a new RNA-based therapy paired with semaglutide preserved more lean mass than semaglutide alone, though it remains far from human use.
Semaglutide in Children: England's Data
A corrected conference abstract from 35 English specialist clinics reports how 406 children and young people fared on semaglutide.
Semaglutide and Heart-Failure Hemodynamics
A new case report describes semaglutide easing heart-failure pressures in one patient, but a single case can't prove a population-wide effect.
GLP-1 drugs and hidradenitis suppurativa
A new review asks whether semaglutide and other GLP-1 drugs could help hidradenitis suppurativa. The evidence is early, and this is not an approved use.
Oral semaglutide 25 mg vs the injection
A Novo Nordisk funded indirect comparison put oral semaglutide 25 mg against the 2.4 mg injection. The weight-loss gap was about one percentage point.
Orforglipron liver safety: pooled data
A pooled analysis of 11,220 people across seven orforglipron phase 3 trials found no confirmed drug-induced liver injury. Here is what it checked, and did not.
Eating disorders in the GLP-1 era
GLP-1 drugs cut binge eating in trials and raise dietary restraint. Here is what clinicians are flagging on eating disorder risk, and what is unmeasured.
GLP-1 Prescribing Without an Indication
A US records study of 92 million adults found GLP-1 prescribing without a documented indication rose 15-fold, and 35.1% of recipients had a normal BMI.